Acute kidney injury risk associated with piperacillin/tazobactam compared with cefepime during vancomycin therapy in hospitalised patients: a cohort study stratified by baseline kidney function

International Journal of Antimicrobial Agents

Volumn 50, Issue 1, 2017, Pages 63-67

  Jeon, Nakyung ^a   Staley, Ben ^b   Klinker, Kenneth P ^a   Hincapie Castillo, Juan ^a   Winterstein, Almut G ^a,c  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Acute kidney injury; Inverse probability of treatment weighting; IPTW; Piperacillin tazobactam; Renal impairment; Vancomycin

Indexed keywords

CEFEPIME; CREATININE; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN; ANTIINFECTIVE AGENT; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ACUTE KIDNEY FAILURE; ADULT; ANTIBIOTIC THERAPY; ARTICLE; COHORT ANALYSIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DRUG SAFETY; ELECTRONIC HEALTH RECORD; FEMALE; HIGH RISK PATIENT; HOSPITAL PATIENT; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; ADOLESCENT; AGED; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ACUTE KIDNEY INJURY; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASE INHIBITORS; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; RETROSPECTIVE STUDIES; RISK ASSESSMENT; VANCOMYCIN; YOUNG ADULT;

EID: 85019626771     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2017.02.023     Document Type: Article

References (36)

1. Moellering, R.C. Jr, Vancomycin: a 50-year reassessment. Clin Infect Dis 42:Suppl. 1 (2006), S3–4.
2. Rybak, M., Lomaestro, B., Rotschafer, J.C., Moellering, R. Jr, Craig, W., Billeter, M., et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm 66 (2009), 82–98.
3. Bamgbola, O., Review of vancomycin-induced renal toxicity: an update. Ther Adv Endocrinol Metab 7 (2016), 136–147.
4. Lau, W.K., Mercer, D., Itani, K.M., Nicolau, D.P., Kuti, J.L., Mansfield, D., et al. Randomized, open-label, comparative study of piperacillin–tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 50 (2006), 3556–3561.
5. Burgess, L.D., Drew, R.H., Comparison of the incidence of vancomycin-induced nephrotoxicity in hospitalized patients with and without concomitant piperacillin–tazobactam. Pharmacotherapy 34 (2014), 670–676.
6. Gomes, D.M., Smotherman, C., Birch, A., Dupree, L., Della Vecchia, B.J., Kraemer, D.F., et al. Comparison of acute kidney injury during treatment with vancomycin in combination with piperacillin–tazobactam or cefepime. Pharmacotherapy 34 (2014), 662–669.
7. Peyko, V., Smalley, S., Cohen, H., Prospective comparison of acute kidney injury during treatment with the combination of piperacillin–tazobactam and vancomycin versus the combination of cefepime or meropenem and vancomycin. J Pharm Pract 30 (2017), 209–213.
8. Karino, S., Kaye, K.S., Navalkele, B., Nishan, B., Salim, M., Solanki, S., et al. Epidemiology of acute kidney injury among patients receiving concomitant vancomycin and piperacillin–tazobactam: opportunities for antimicrobial stewardship. Antimicrob Agents Chemother 60 (2016), 3743–3750.
9. Moenster, R.P., Linneman, T.W., Finnegan, P.M., Hand, S., Thomas, Z., McDonald, J.R., Acute renal failure associated with vancomycin and β-lactams for the treatment of osteomyelitis in diabetics: piperacillin–tazobactam as compared with cefepime. Clin Microbiol Infect, 20, 2014 O384–9.
10. Hammond, D.A., Smith, M.N., Painter, J.T., Meena, N.K., Lusardi, K., Comparative incidence of acute kidney injury in critically ill patients receiving vancomycin with concomitant piperacillin–tazobactam or cefepime: a retrospective cohort study. Pharmacotherapy 36 (2016), 463–471.
11. Davies, S.W., Efird, J.T., Guidry, C.A., Dietch, Z.C., Willis, R.N., Shah, P.M., et al. Top guns: the ‘Maverick’ and ‘Goose’ of empiric therapy. Surg Infect (Larchmt) 17 (2016), 38–47.
12. Kim, T., Kandiah, S., Patel, M., Rab, S., Wong, J., Xue, W., et al. Risk factors for kidney injury during vancomycin and piperacillin/tazobactam administration, including increased odds of injury with combination therapy. BMC Res Notes, 8, 2015, 579.
13. Chawla, L.S., Kimmel, P.L., Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 82 (2012), 516–524.
14. McDonald, J.S., McDonald, R.J., Lieske, J.C., Carter, R.E., Katzberg, R.W., Williamson, E.E., et al. Risk of acute kidney injury, dialysis, and mortality in patients with chronic kidney disease after intravenous contrast material exposure. Mayo Clin Proc 90 (2015), 1046–1053.
15. Leonberg-Yoo, A.K., Tighiouart, H., Levey, A.S., Beck, G.J., Sarnak, M.J., Urine potassium excretion, kidney failure, and mortality in CKD. Am J Kidney Dis 69 (2017), 341–349.
16. Hsu, C.Y., Ordonez, J.D., Chertow, G.M., Fan, D., McCulloch, C.E., Go, A.S., The risk of acute renal failure in patients with chronic kidney disease. Kidney Int 74 (2008), 101–107.
17. Waikar, S.S., Liu, K.D., Chertow, G.M., Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 3 (2008), 844–861.
18. Panwar, B., Johnson, V.A., Patel, M., Balkovetz, D.F., Risk of vancomycin-induced nephrotoxicity in the population with chronic kidney disease. Am J Med Sci 345 (2013), 396–399.
19. Andrassy, K.M., Comments on ‘KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease’. Kidney Int 84 (2013), 622–623.
20. Khwaja, A., KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract 120 (2012), c179–84.
21. Mamdani, M., Sykora, K., Li, P., Normand, S.L., Streiner, D.L., Austin, P.C., et al. Reader's guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 330 (2005), 960–962.
22. Austin, P.C., Stuart, E.A., Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies. Stat Med 34 (2015), 3661–3679.
23. Brookhart, M.A., Wyss, R., Layton, J.B., Sturmer, T., Propensity score methods for confounding control in nonexperimental research. Circ Cardiovasc Qual Outcomes 6 (2013), 604–611.
24. Kellum, J.A., Murugan, R., Effect of non-severe acute kidney injury on clinical outcomes in critically ill patients. Crit Care, 20, 2016, 159.
25. Hoste, E.A., Bagshaw, S.M., Bellomo, R., Cely, C.M., Colman, R., Cruz, D.N., et al. Epidemiology of acute kidney injury in critically ill patients: the multinational AKI-EPI study. Intensive Care Med 41 (2015), 1411–1423.
26. Forni, L.G., Dawes, T., Sinclair, H., Cheek, E., Bewick, V., Dennis, M., et al. Identifying the patient at risk of acute kidney injury: a predictive scoring system for the development of acute kidney injury in acute medical patients. Nephron Clin Pract 123 (2013), 143–150.
27. Thakar, C.V., Christianson, A., Almenoff, P., Freyberg, R., Render, M.L., Degree of acute kidney injury before dialysis initiation and hospital mortality in critically ill patients. Int J Nephrol, 2013, 2013 827459.
28. Sileanu, F.E., Murugan, R., Lucko, N., Clermont, G., Kane-Gill, S.L., Handler, S.M., et al. AKI in low-risk versus high-risk patients in intensive care. Clin J Am Soc Nephrol 10 (2015), 187–196.
29. Lin, J., Fernandez, H., Shashaty, M.G., Negoianu, D., Testani, J.M., Berns, J.S., et al. False-positive rate of AKI using consensus creatinine-based criteria. Clin J Am Soc Nephrol 10 (2015), 1723–1731.
30. Pan, H.C., Wu, P.C., Wu, V.C., Yang, Y.F., Huang, T.M., Shiao, C.C., et al. A nationwide survey of clinical characteristics, management, and outcomes of acute kidney injury (AKI)—patients with and without preexisting chronic kidney disease have different prognoses. Medicine (Baltimore), 95, 2016, e4987.
31. Perazella, M.A., Luciano, R.L., Review of select causes of drug-induced AKI. Expert Rev Clin Pharmacol 8 (2015), 367–371.
32. Coca, S.G., Garg, A.X., Swaminathan, M., Garwood, S., Hong, K., Thiessen-Philbrook, H., et al. Preoperative angiotensin-converting enzyme inhibitors and angiotensin receptor blocker use and acute kidney injury in patients undergoing cardiac surgery. Nephrol Dial Transplant 28 (2013), 2787–2799.
33. Solomon, R.J., Natarajan, M.K., Doucet, S., Sharma, S.K., Staniloae, C.S., Katholi, R.E., et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. Circulation 115 (2007), 3189–3196.
34. Laskey, W., Aspelin, P., Davidson, C., Rudnick, M., Aubry, P., Kumar, S., et al. Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. Am Heart J 158 (2009), 822–828 e3.
35. Chertow, G.M., Burdick, E., Honour, M., Bonventre, J.V., Bates, D.W., Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 16 (2005), 3365–3370.
36. Robins, J.M., Hernan, M.A., Brumback, B., Marginal structural models and causal inference in epidemiology. Epidemiology 11 (2000), 550–560.